Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 9/20 | 0.53 |
| ▸ | MAOB | P27338 | 9/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.46 |
| ▸ | TDP2 | O95551 | 2/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.42 |
| ▸ | TYMS | P04818 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12500758 | 0.96 | MAOA (0.48) | MAOAMAOBCYP2A6PRKCIMEN1 | |
| SCHEMBL10138376 | 0.88 | PBRM1 (0.59) | MAOAMAOBCYP2A6PBRM1TDP2 | |
| SCHEMBL31695158 | 0.88 | PBRM1 (0.59) | MAOAMAOBCYP2A6PBRM1TDP2 | |
| SCHEMBL315147 | 0.84 | MAOA (0.61) | MAOAMAOBCYP2A6PRKCIMEN1 | |
| SCHEMBL23273176 | 0.80 | MAOA (0.59) | MAOAMAOBCYP2A6PRKCIMEN1 | |
| SCHEMBL5543621 | 0.78 | MAOA (0.55) | MAOAMAOBCYP2A6PRKCIMEN1 | |
| SCHEMBL6370185 | 0.77 | TDP2 (0.48) | MAOBPBRM1TDP2TYMSTGM2 | |
| SCHEMBL8501316 | 0.77 | TDP2 (0.58) | MAOAMAOBPBRM1TDP2TYMS | |
| SCHEMBL18533320 | 0.76 | TDP2 (0.37) | MAOAMAOBCYP2A6TDP2TYMS | |
| SCHEMBL769238 | 0.76 | MAOA (0.53) | MAOAMAOBCYP2A6PRKCIMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002426-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | RECURIUM IP HOLDINGS, LLC | 2023-01-05 | — | — | US | disclosed |
| WO-2021097139-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | RECURIUM IP HOLDINGS, LLC (US) | 2021-05-20 | — | — | WO | disclosed |
| US-10882865-B2 | Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity | NORTHWESTERN UNIVERSITY (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200071334-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | NORTHWESTERN UNIVERSITY (US) | 2020-03-05 | — | — | US | disclosed |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
| EP-2240029-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corp. (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009089305-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009089305-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-07-16 | — | — | WO | disclosed |
| EP-0513974-B1 | Novel benzo-fused lactams that promote the release of growth hormone | MERCK & CO INC (US) | 1996-09-04 | — | — | EP | disclosed |
| US-5385947-A | For prevention of nerve damage due to reduction of blood or oxygen supplies | HOFFMANN-LA ROCHE INC. (US) | 1995-01-31 | — | — | US | disclosed |
| EP-0606661-A1 | Octahydrophenanthrene derivatives and their use as NMDA-Antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1994-07-20 | — | — | EP | disclosed |
| US-5310737-A | Benzo-fused lactams that promote the release of growth hormone | MERCK & CO., INC. (US) | 1994-05-10 | — | — | US | disclosed |
| US-5206235-A | Animal growth regulators; stimulants | MERCK & CO., INC. (US) | 1993-04-27 | — | — | US | disclosed |
| EP-0513974-A1 | Novel benzo-fused lactams that promote the release of growth hormone | MERCK & CO. INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| CN-1066070-A | Promote the new benzo-fused lactams that tethelin discharges | MERCK & CO INC (US) | 1992-11-11 | — | — | CN | disclosed |
| WO-1992016524-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| US-4048330-A | Compositions containing 2-(6'-substituted-2'-naphthyl)acetic acid esters used for treating inflammation, pain or pyrexia | SYNTEX CORPORATION (US) | 1977-09-13 | — | — | US | disclosed |
| US-4009197-A | 2-(6-Substituted-2'-naphthyl) acetic acid derivatives and the salts and esters thereof | SYNTEX CORPORATION (PM) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882865-B2 | Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity | GAA, GBA1, GBA3 | MAOA 1217/4885MAOB 697/4885CYP2A6 2338/4885 |
| US-20200071334-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | GAA, GBA3, GBA1 | MAOA 1147/4885MAOB 608/4885CYP2A6 2162/4885 |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | TSLP, NFATC1, IL5 | MAOA 2191/4885MAOB 2102/4885CYP2A6 796/4885 |
| US-20230002426-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | ADH1A, ADH1C, ADH5 | MAOA 2803/4885MAOB 1691/4885CYP2A6 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.